{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:15:31Z","timestamp":1791515731585,"version":"4.3.4"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003136","name":"Philanthropia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009691","name":"Nuovo-Soldati","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejca.2019.06.020","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T17:33:12Z","timestamp":1565631192000},"page":"44-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy"],"prefix":"10.1016","volume":"119","author":[{"given":"Ahmed","family":"Mekki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1322-0710","authenticated-orcid":false,"given":"Laurent","family":"Dercle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lichtenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaida","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-3019","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Champiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Chouzenoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Balleyguier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Ammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.ejca.2019.06.020_bib2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.coi.2006.01.011","article-title":"Principles and use of anti-CTLA4 antibody in human cancer immunotherapy","volume":"18","author":"Peggs","year":"2006","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"10.1016\/j.ejca.2019.06.020_bib3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/phar.1643","article-title":"Immune checkpoint inhibitors: new insights and current place in cancer therapy","volume":"35","author":"La-Beck","year":"2015","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"4","key":"10.1016\/j.ejca.2019.06.020_bib4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2019.06.020_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2019.06.020_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejca.2019.06.020_bib7","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2019.06.020_bib8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2019.06.020_bib9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/03007995.2017.1279132","article-title":"Targeting the PD-1 pathway: a new hope for gastrointestinal cancers","volume":"33","author":"Bilgin","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"19","key":"10.1016\/j.ejca.2019.06.020_bib10","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.06.020_bib11","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd.2018.210","article-title":"Trial watch: the clinical trial landscape for PD1\/PDL1 immune checkpoint inhibitors","volume":"17","author":"Tang","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2967\/jnumed.117.193011","article-title":"18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with hodgkin lymphoma treated by anti\u2013programmed death 1 immune checkpoint inhibitor","volume":"59","author":"Dercle","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2019.06.020_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2017.12.015","article-title":"Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma","volume":"91","author":"Dercle","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bulcan.2017.11.008","article-title":"Le lymphome de Hodgkin\u202f: strat\u00e9gies th\u00e9rapeutiques actuelles et futures","volume":"105","author":"Turpin","year":"2018","journal-title":"Bull Cancer (Paris)"},{"issue":"4","key":"10.1016\/j.ejca.2019.06.020_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.06.020_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.017","article-title":"Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody","volume":"66","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2019.06.020_bib17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.06.020_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1","volume":"96","author":"Mekki","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2019.06.020_bib19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1148\/rg.352140121","article-title":"Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events","volume":"35","author":"Kwak","year":"2015","journal-title":"RadioGraphics"},{"issue":"4","key":"10.1016\/j.ejca.2019.06.020_bib20","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2019.06.020_bib21","doi-asserted-by":"crossref","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"230","key":"10.1016\/j.ejca.2019.06.020_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.ejca.2019.06.020_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.seminoncol.2018.09.002","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"45","author":"Solinas","year":"2018","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2019.06.020_bib25","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2019.06.020_bib26","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.31.8.998","article-title":"Pituitary metastasis: incidence in cancer patients and clinical differentiation from pituitary adenoma","volume":"31","author":"Max","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.ejca.2019.06.020_bib27","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2019.06.020_bib28","series-title":"MRI of the pituitary gland","author":"Bonneville","year":"2016"},{"issue":"9","key":"10.1016\/j.ejca.2019.06.020_bib29","doi-asserted-by":"crossref","DOI":"10.4158\/EP-2017-0249","article-title":"Ipilimumab-induced secondary hypophysitis","volume":"24","author":"Cheema","year":"2018","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.ejca.2019.06.020_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0b013e3182639765","article-title":"Detection of early onset of hypophysitis by 18f-fdg Pet-ct in a patient with advanced stage melanoma treated with ipilimumab","volume":"38","author":"van der Hiel","year":"2013","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.ejca.2019.06.020_bib31","first-page":"593","article-title":"Cytotoxic T-lymphocyte\u2013associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer","volume":"28","author":"Blansfield","year":"2005","journal-title":"J Immunother Hagerstown MD 1997"},{"issue":"2","key":"10.1016\/j.ejca.2019.06.020_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.ejca.2019.06.020_bib33","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40618-015-0301-z","article-title":"Ipilimumab-induced hypophysitis: review of the literature","volume":"38","author":"Araujo","year":"2015","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"10.1016\/j.ejca.2019.06.020_bib34","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3174\/ajnr.A1623","article-title":"Ipilimumab-induced hypophysitis: MR imaging findings","volume":"30","author":"Carpenter","year":"2009","journal-title":"Am J Neuroradiol"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11606-017-4135-6","article-title":"Checkpoint inhibitor-associated hypophysitis","volume":"33","author":"Chang","year":"2018","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.ejca.2019.06.020_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clineuro.2014.06.011","article-title":"Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis","volume":"125","author":"Chodakiewitz","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.ejca.2019.06.020_bib38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/01658107.2017.1368090","article-title":"Ipilimumab-induced adenohypophysitis and orbital apex syndrome: importance of early diagnosis and management","volume":"42","author":"Hassanzadeh","year":"2017","journal-title":"Neuro Ophthalmol"},{"issue":"8","key":"10.1016\/j.ejca.2019.06.020_bib39","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaoncol.2015.2537","article-title":"Melanoma and a headache","volume":"1","author":"Johnson","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"MECHANISMS IN ENDOCRINOLOGY: ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.ejca.2019.06.020_bib41","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/CMR.0b013e32832e0bff","article-title":"Anti-ctla-4 therapy-related autoimmune hypophysitis in a melanoma patient","volume":"19","author":"Kaehler","year":"2009","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/js.2017-00414","article-title":"Two cases of atezolizumab-induced hypophysitis","volume":"2","author":"Kanie","year":"2017","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ejca.2019.06.020_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4137\/CMED.S22469","article-title":"Immune checkpoint inhibitor therapy associated hypophysitis","volume":"8","author":"Mahzari","year":"2015","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"10.1016\/j.ejca.2019.06.020_bib44","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/570293","article-title":"Anticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review","author":"Majchel","year":"2015","journal-title":"Case Rep Endocrinol"},{"issue":"3","key":"10.1016\/j.ejca.2019.06.020_bib45","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s12020-014-0199-9","article-title":"Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports","volume":"47","author":"Marlier","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.ejca.2019.06.020_bib46","first-page":"2018https","article-title":"Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies","author":"Gunawan","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"4","key":"10.1016\/j.ejca.2019.06.020_bib47","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2169\/internalmedicine.9074-17","article-title":"Isolated adrenocorticotropin deficiency due to nivolumab-induced hypophysitis in a patient with advanced lung adenocarcinoma: a case report and literature review","volume":"57","author":"Ohara","year":"2018","journal-title":"Intern Med"},{"issue":"10","key":"10.1016\/j.ejca.2019.06.020_bib48","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1507\/endocrj.EJ16-0161","article-title":"Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma","volume":"63","author":"Okano","year":"2016","journal-title":"Endocr J"},{"key":"10.1016\/j.ejca.2019.06.020_bib49","article-title":"Immunotherapy-induced autoimmune hypophysitis","volume":"1078155217727142","author":"Valecha","year":"2017","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib50","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.acra.2016.08.005","article-title":"Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT","volume":"24","author":"Wachsmann","year":"2017","journal-title":"Acad Radiol"},{"issue":"3","key":"10.1016\/j.ejca.2019.06.020_bib51","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.radcr.2018.03.011","article-title":"Ipilimumab cystic hypophysitis mimicking metastatic melanoma","volume":"13","author":"Wallace","year":"2018","journal-title":"Radiol Case Rep"},{"key":"10.1016\/j.ejca.2019.06.020_bib52","series-title":"A case of pituitary hypophysitis following treatment with ipilimumab","author":"Iqbal","year":"2016"},{"issue":"6","key":"10.1016\/j.ejca.2019.06.020_bib53","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11102-013-0542-9","article-title":"Clinical and biochemical characteristic features of metastatic cancer to the sella turcica: an analytical review","volume":"17","author":"Al-Aridi","year":"2014","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.ejca.2019.06.020_bib54","first-page":"S242","article-title":"Pituitary metastasis as a presenting manifestation of silent systemic malignancy: a retrospective analysis of four cases","volume":"15","author":"Dutta","year":"2011","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-008-9586-5","article-title":"Pituitary metastasis from medullary carcinoma of thyroid: case report and review of literature","volume":"89","author":"Bhatoe","year":"2008","journal-title":"J Neuro Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2019.06.020_bib56","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/BF03346341","article-title":"Pituitary metastasis of breast cancer confirmed by fluorine-18 fluorodeoxyglucose positron emission tomography: a case report","volume":"30","author":"Ersoy","year":"2007","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"10.1016\/j.ejca.2019.06.020_bib57","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jocn.2010.05.006","article-title":"Small cell lung cancer metastasis in the pituitary gland presenting with seizures and headache","volume":"18","author":"Fridley","year":"2011","journal-title":"J Clin Neurosci"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11102-007-0038-6","article-title":"Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review","volume":"11","author":"Goglia","year":"2008","journal-title":"Pituitary"},{"issue":"8","key":"10.1016\/j.ejca.2019.06.020_bib59","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1055\/s-2007-981456","article-title":"Two rare cases of pituitary metastases from breast and kidney cancers","volume":"115","author":"Go\u0142kowski","year":"2007","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"10.1016\/j.ejca.2019.06.020_bib60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11102-007-0047-5","article-title":"Symptomatic pituitary metastases from renal cell carcinoma","volume":"10","author":"Gopan","year":"2007","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib61","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11102-014-0552-2","article-title":"Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis","volume":"18","author":"He","year":"2015","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ejca.2019.06.020_bib62","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1111\/ajco.12353","article-title":"Solitary pituitary metastasis from HER2-positive breast cancer","volume":"13","author":"Kam","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2019.06.020_bib63","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1023\/A:1023994604919","article-title":"Hepatocellular carcinoma metastasis in the pituitary gland: case report and review of the literature","volume":"63","author":"Karamouzis","year":"2003","journal-title":"J Neuro Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2019.06.020_bib64","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1378\/chest.105.3.951","article-title":"Panhypopituitarism caused by solitary parasellar metastasis from lung cancer","volume":"105","author":"Ko","year":"1994","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.ejca.2019.06.020_bib65","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/BF03345815","article-title":"Metastatic renal cell carcinoma to the pituitary gland presenting with hypopituitarism","volume":"15","author":"Koshiyama","year":"1992","journal-title":"J Endocrinol Invest"},{"issue":"04","key":"10.1016\/j.ejca.2019.06.020_bib66","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-2008-1062742","article-title":"Keyhole surgery for isolated pituitary stalk metastatic tumors: a case report and review of the literature","volume":"51","author":"Lin","year":"2008","journal-title":"Min - Minim Invasive Neurosurg."},{"issue":"10","key":"10.1016\/j.ejca.2019.06.020_bib67","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2176\/nmc.cr2012-0068","article-title":"Pituitary apoplexy caused by hemorrhage from pituitary metastatic melanoma: case report","volume":"53","author":"Masui","year":"2013","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib68","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12029-013-9554-y","article-title":"Pituitary metastasis of colon adenocarcinoma: a rare occurrence","volume":"45","author":"Ozturk","year":"2014","journal-title":"J Gastrointest Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2019.06.020_bib69","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.3816\/CBC.2009.n.047","article-title":"Panhypopituitarism due to metastases to the hypothalamus and the pituitary resulting from primary breast cancer: a case report and review of the literature","volume":"9","author":"Peppa","year":"2009","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2019.06.020_bib70","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3171\/jns.2004.101.6.1053","article-title":"Resolution of diabetes insipidus following gamma knife surgery for a solitary metastasis to the pituitary stalk: case report","volume":"101","author":"Piedra","year":"2004","journal-title":"J Neurosurg"},{"issue":"8","key":"10.1016\/j.ejca.2019.06.020_bib71","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2009.146","article-title":"Prostate adenocarcinoma metastasis in the pituitary gland","volume":"66","author":"Riemenschneider","year":"2009","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.ejca.2019.06.020_bib72","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1590\/2359-3997000000139","article-title":"Pituitary metastasis of lung neuroendocrine carcinoma: case report and literature review","volume":"59","author":"Siqueira","year":"2015","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ejca.2019.06.020_bib73","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.anndiagpath.2006.08.007","article-title":"Medullary thyroid carcinoma metastatic to the pituitary gland: an unusual site of metastasis","volume":"12","author":"Williams","year":"2008","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"10.1016\/j.ejca.2019.06.020_bib74","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/2193-1801-2-467","article-title":"Pituitary gland metastasis from rectal cancer: report of a case and literature review","volume":"2","author":"Ratti","year":"2013","journal-title":"SpringerPlus"},{"issue":"4","key":"10.1016\/j.ejca.2019.06.020_bib75","first-page":"277","article-title":"What\u2019s in the image? Pituitary metastasis from papillary carcinoma of the thyroid: a case report and a comprehensive review of the literature","volume":"1","author":"Stojanovi\u0107","year":"2013","journal-title":"Eur Thyroid J"},{"issue":"4","key":"10.1016\/j.ejca.2019.06.020_bib76","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/000456329803500410","article-title":"Renal carcinoma presenting with adrenocortical insufficiency due to a pituitary metastasis","volume":"35","author":"Beckett","year":"1998","journal-title":"Ann Clin Biochem"},{"issue":"5","key":"10.1016\/j.ejca.2019.06.020_bib77","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF03346322","article-title":"An isolated pituitary metastasis as presentation of a differentiated hepatocellular carcinoma mimicking a non-functioning macroadenoma","volume":"30","author":"Moreno-Perez","year":"2007","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.ejca.2019.06.020_bib78","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0b013e31828da679","article-title":"A rare case of non\u2013small cell lung cancer metastasizing to the pituitary gland: detection with 18f-fdg Pet-ct","volume":"39","author":"Agarwal","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1016\/j.ejca.2019.06.020_bib79","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12020-012-9806-9","article-title":"Pituitary metastasis of thyroid cancer","volume":"43","author":"Barbaro","year":"2013","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.ejca.2019.06.020_bib80","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10147-004-0458-5","article-title":"Symptomatic metastases to the pituitary infundibulum resulting from primary breast cancer","volume":"10","author":"Kurkjian","year":"2005","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2019.06.020_bib81","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11102-018-0899-x","article-title":"Twelve cases of pituitary metastasis: a case series and review of the literature","volume":"21","author":"Castle-Kirszbaum","year":"2018","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.ejca.2019.06.020_bib82","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/hed.20911","article-title":"Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer","volume":"31","author":"Santarpia","year":"2009","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2019.06.020_bib83","doi-asserted-by":"crossref","first-page":"7","DOI":"10.12659\/AJCR.901032","article-title":"Pituitary metastasis from renal cell carcinoma: description of a case report","volume":"18","author":"Wendel","year":"2017","journal-title":"Am J Case Rep"},{"issue":"2","key":"10.1016\/j.ejca.2019.06.020_bib84","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11060-009-0025-z","article-title":"Pituitary metastasis of Merkel cell carcinoma","volume":"97","author":"Feletti","year":"2010","journal-title":"J Neuro Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2019.06.020_bib85","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3340\/jkns.2012.51.2.94","article-title":"A case of pituitary metastasis from breast cancer that presented as left visual disturbance","volume":"51","author":"Kim","year":"2012","journal-title":"J Korean Neurosurg Soc"},{"issue":"4","key":"10.1016\/j.ejca.2019.06.020_bib86","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jcrpr.2016.05.009","article-title":"Solitary pituitary metastasis from breast cancer that presented as visual field defect","volume":"3","author":"Chu","year":"2016","journal-title":"J Cancer Res Pract"},{"issue":"8","key":"10.1016\/j.ejca.2019.06.020_bib87","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jocn.2004.11.020","article-title":"Symptomatic pituitary metastasis of malignant thymoma","volume":"12","author":"Kanayama","year":"2005","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.ejca.2019.06.020_bib88","doi-asserted-by":"crossref","first-page":"896","DOI":"10.12659\/AJCR.909523","article-title":"Pituitary metastasis of thyroid carcinoma: a case report","volume":"19","author":"Mota","year":"2018","journal-title":"Am J Case Rep"},{"issue":"2","key":"10.1016\/j.ejca.2019.06.020_bib89","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11102-006-8326-0","article-title":"Pituitary metastasis masquerading as non-functioning pituitary adenoma in a woman with adenocarcinoma lung","volume":"9","author":"Rajput","year":"2006","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.ejca.2019.06.020_bib90","first-page":"225","article-title":"Pituitary metastasis of renal cell carcinoma\u202f: a case report","volume":"42","author":"Bi\u0161of","year":"2009","journal-title":"Radiol Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2019.06.020_bib91","first-page":"475","article-title":"Diabetes insipidus due to pituitary metastasis in a woman with lung adenocarcinoma: a case report","volume":"6","author":"Hsiao","year":"2011","journal-title":"Cent Eur J Med"},{"key":"10.1016\/j.ejca.2019.06.020_bib92","article-title":"Thyroid carcinoma with pituitary metastases: 2 case reports and literature review","volume":"2015","author":"Lim","year":"2015","journal-title":"Case Rep Endocrinol"},{"issue":"5","key":"10.1016\/j.ejca.2019.06.020_bib93","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.06.020_bib94","series-title":"Endotext","article-title":"Hypophysitis","author":"Prete","year":"2018"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919304022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919304022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:24:43Z","timestamp":1760732683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919304022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":94,"alternative-id":["S0959804919304022"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.06.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}